Synonyms: BAY-E-9736 | Nimotop®
nimodipine is an approved drug (FDA (1988))
Compound class:
Synthetic organic
Comment: Nimodipine is a dihydropyridine calcium channel blocker.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖View more information in the IUPHAR Pharmacology Education Project: nimodipine |
|
References |
1. Dietz JD, Du S, Bolten CW, Payne MA, Xia C, Blinn JR, Funder JW, Hu X. (2008)
A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension, 51 (3): 742-8. [PMID:18250364] |
2. Safa P, Boulter J, Hales TG. (2001)
Functional properties of Cav1.3 (alpha1D) L-type Ca2+ channel splice variants expressed by rat brain and neuroendocrine GH3 cells. J Biol Chem, 276 (42): 38727-37. [PMID:11514547] |
3. Schiller IC, Jacobson KA, Wen Z, Malisetty A, Schmalzing G, Markwardt F. (2022)
Dihydropyridines Potentiate ATP-Induced Currents Mediated by the Full-Length Human P2X5 Receptor. Molecules, 27 (6). [PMID:35335209] |
4. Verkman AS, Galietta LJ. (2009)
Chloride channels as drug targets. Nat Rev Drug Discov, 8 (2): 153-71. [PMID:19153558] |
5. Xu W, Lipscombe D. (2001)
Neuronal Ca(V)1.3alpha(1) L-type channels activate at relatively hyperpolarized membrane potentials and are incompletely inhibited by dihydropyridines. J Neurosci, 21 (16): 5944-51. [PMID:11487617] |